Price T Rowe Associates Inc. MD Has $10.45 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Price T Rowe Associates Inc. MD increased its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 16.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,295,025 shares of the company's stock after buying an additional 180,140 shares during the quarter. Price T Rowe Associates Inc. MD owned about 1.84% of ORIC Pharmaceuticals worth $10,452,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ORIC. Barclays PLC raised its position in shares of ORIC Pharmaceuticals by 111.2% during the 3rd quarter. Barclays PLC now owns 107,261 shares of the company's stock worth $1,100,000 after buying an additional 56,474 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of ORIC Pharmaceuticals by 26.1% during the third quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock worth $9,067,000 after acquiring an additional 196,804 shares during the period. JPMorgan Chase & Co. grew its stake in shares of ORIC Pharmaceuticals by 3.8% during the third quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company's stock worth $361,000 after buying an additional 1,279 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of ORIC Pharmaceuticals by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 162,909 shares of the company's stock valued at $1,315,000 after purchasing an additional 24,947 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in ORIC Pharmaceuticals by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company's stock worth $121,000 after purchasing an additional 1,395 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

ORIC Pharmaceuticals Stock Up 10.4 %

Shares of ORIC stock traded up $0.49 during trading hours on Thursday, hitting $5.19. 139,755 shares of the company's stock traded hands, compared to its average volume of 640,111. The stock has a market cap of $368.93 million, a price-to-earnings ratio of -2.85 and a beta of 1.37. The stock's fifty day simple moving average is $5.99 and its two-hundred day simple moving average is $8.12. ORIC Pharmaceuticals, Inc. has a 12-month low of $3.90 and a 12-month high of $14.67.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.09. On average, equities analysts forecast that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday. Wedbush reissued an "outperform" rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Oppenheimer decreased their price objective on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday. Guggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $19.17.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.